Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
Status:
Completed
Trial end date:
2020-04-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the activity of Sym004, a recombinant antibody mixture
that specifically binds to EGFR, in patients diagnosed with recurrent glioblastoma whose
tumor is EGFR amplified. This is a phase 2 study that will accrue patients with WHO grade IV
recurrent malignant glioma (glioblastoma or gliosarcoma) in two cohorts to assess the
efficacy of Sym004.